Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies

• Main Authors: Delphine Planas (Author), Isabelle Staropoli (Author), Cyril Planchais (Author), Emilie Yab (Author), Banujaa Jeyarajah (Author), Yannis Rahou (Author), Matthieu Prot (Author), Florence Guivel-Benhassine (Author), Frederic Lemoine (Author), Vincent Enouf (Author), Etienne Simon-Loriere (Author), Hugo Mouquet (Author), Marie-Anne (Author), Olivier Schwartz (Author)
• Format: Book
• Published: Case Western Reserve University, 2024-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: First-generation anti-SARS-CoV-2 monoclonal antibodies (mAbs) used for prophylaxis or therapeutic purposes in immunocompromised patients have been withdrawn because of the emergence of resistant Omicron variants. In 2024, 2 novel mAbs, VYD222/Pemivibart and AZD3152/Sipavibart, were appro...